Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

In Alzheimer's disease (AD), amyloid β-protein (Aβ) production by regulated intramembrane proteolysis is crucial for pathogenicity. An unusual intramembrane cleavage generates various Aβ ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

At most, we observed a slight astrocyte response using immunostaining with antibody against glia fibrillary acidic protein (data not shown). These data indicate that clearance of amyloid-β after ...

researchers studying the autopsied brains of people with Alzheimer’s discovered that they were clogged with sticky plaques made from beta amyloid proteins and toxic tangles made of a protein ...

A method for slowing disease progress in Alzheimer's patients may also delay onset in people predisposed to the disease who are yet to show symptoms. The just-published results from a clinical trial ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

Although there are many outstanding questions about Alzheimer’s and a significant lack of effective drugs, scientists believe a protein called amyloid-beta plays an important role in the condition.

In one particularly promising approach, peptides designed to bind amyloid beta, the protein that forms plaques in Alzheimer’s disease, have shown the ability to both penetrate the brain and ...

"Although studies have shown that supersaturation is a necessary condition for amyloid fibril formation, the factors that actually induce protein aggregation in supersaturated fluids remain unclear." ...